Oxurion NV Overview
Oxurion is the shell of a former Belgian ophthalmology biotech. It has been repurposed into a listed vehicle that acquires majority stakes in small European CROs. The heritage is substantial. As ThromboGenics, the company created the pharmacological vitreolysis category with JETREA (ocriplasmin), which was approved in 54 countries. After its last clinical asset, THR-149, failed in November 2023, the company avoided bankruptcy only through a rescue agreement with its convertible-bond investor, Atlas Special Opportunities. It then went through a court-supervised private reorganisation in 2024 and stopped all internal R&D in August 2025. Today its only operating asset is a 72% stake in Axiodis CRO, a Toulouse biometrics and clinical-data-management specialist with about €1.0 million in revenue. Axiodis owns the Exagis CDMS platform. Oxurion is pursuing a buy-and-build strategy: an international CRO LOI (March 2026) and exclusive talks on Eclevar, a MedTech CRO (September 2026). Equity is negative, cash is close to zero, and funding depends entirely on conditional Atlas convertible tranches.
Company's own description (latest filings)
The FY2025 Annual Report describes Oxurion as moving from a pure biopharmaceutical R&D model to an integrated European platform of clinical research services. It plans to get there by acquiring majority stakes in promising pharmaceutical subcontractors (CROs). The stated aim is to improve clinical development through clinical data management, biometrics, eClinical technologies (eCRF), regulatory affairs and statistical analysis.
The H1 2026 Interim Report describes the group as a "technology-enabled European clinical research group." It combines specialised CRO services, proprietary software (Exagis) and external growth. The client focus is pharmaceutical, biotechnology and medical-device sponsors, with emphasis on clinical data, biometrics and eClinical technologies. Press releases from October 2026 describe the company as building a technology-enabled clinical research and software platform.
Independent characterisation
Oxurion is in practice a micro-cap listed holding company with three characteristics:
-
One small operating subsidiary (Axiodis CRO). Axiodis generated about €1.0 million of operating income in calendar 2025 and has been profitable at the net level since inception.
-
A holding-company cost base larger than the subsidiary's revenue. This covers listing, reporting, M&A and legacy liabilities. Group G&A was €2.3 million in FY2025 against €0.6 million of consolidated revenue.
-
A financing structure dominated by one investor, Atlas Special Opportunities II LLC. Atlas is at once a convertible bondholder, lender, second-ranking pledgee and, intermittently, the largest shareholder. The FY2025 Annual Report states that Atlas is presumed to have de facto control under Article 1:14 of the Belgian Code of Companies and Associations (BCCA).
Business and revenue model
| Dimension | Current model (FY2025–H1 2026) | Legacy model (to FY2023) |
|---|---|---|
| Core activity | Outsourced clinical biometrics: data management, biostatistics, statistical programming, eCRF/CDMS | Ophthalmic drug R&D (DME, AMD, GA); JETREA commercialisation |
| Revenue type | Service fees per study mandate (project-based contracts); platform use embedded in services | Product sales (JETREA vials) and royalties |
| Product vs service vs licensing mix | ~100% services (FY2025: €555k; H1 2026: €591k) | FY2023: product sales €0.2M, royalties €0.1M (statutory) |
| Subscription / SaaS | Not reported separately. Exagis is being productised as a broader eClinical suite (roadmap) | — |
| Value-chain position | Tier-3 specialist / functional service provider. Works directly for sponsors and as subcontractor to full-service CROs (e.g., the KYomed INNOV & CEISO partnership) | Drug originator / licensor |
| Customers | Pharma, biotech, medtech and academic sponsors. About 10 clients; top 3 ≈ 80% of revenue; largest ≈ 50% (Source: AR FY2025, risk 3.5.2.1) | Ophthalmologists via distributors (Inceptua, Alcon, earlier Novartis) |
| End-markets | Clinical development services (drugs and medical devices); new focus offerings in GLP-1, peptides and biosimilars (June 2026) | Retinal disease therapeutics |
| Geography | France-based delivery; operational footprint in "more than a dozen countries" (H1 2026 report) | Global |
Contracting model
Axiodis typically signs individual service agreements per trial rather than long-term framework contracts (AR FY2025). It must therefore keep winning new mandates. Revenue visibility is short, and there is no disclosed backlog.
Strategy
Stated strategy (themes from AR FY2025 and H1 2026)
Vision: management's stated ambition is to become a leading European player in pharmaceutical outsourcing, centred on clinical data.
Platform strategy: integrate Axiodis's eCRF, data-management and biometrics capabilities with complementary regulatory, eClinical and statistical expertise into one clinical-data platform.
Execution focus: move capital and headcount from internal R&D to CRO operations and technology, funded by Atlas.
Profitability and selectivity: target profitable acquisitions with differentiated capabilities, growth prospects and a direct fit with the data platform.
"One-stop shop": cover the clinical development continuum from trial design to market access.
Technology: use Exagis as the common backbone and expand it into an eClinical suite (randomisation, supply, analytics, AI-assisted tools).
Initiatives (last 24 months)
| Date | Initiative | Status | Target / metric | Source |
|---|---|---|---|---|
| Jul 2024 – Apr 2025 | Acquisition of a majority stake in a French stem-cell / beta-cell CRO | Terminated 25 Apr 2025 (target's results came in better than expected, so terms were not agreed) | — | PR 25 Apr 2025 |
| Aug–Nov 2024 | Private judicial reorganisation (debt restructuring) | Completed | Debt cut from €14.7M to €11.2M | PRs Sep and Nov 2024 |
| Mar–Aug 2025 | Axiodis CRO acquisition (72%) | Completed 1 Aug 2025 | Axiodis targets >€2M revenue and 20% EBITDA by 2027 | PRs 16 May and 4 Aug 2025 |
| Jul 2025 – Jan 2026 | Treasury diversification into Bitcoin/Ethereum (€10M, then €30M Atlas convertible facility) | Suspended 19 Jan 2026 | — | PRs 22 Jul 2025, 4 Aug 2025, 19 Jan 2026 |
| 7 Aug 2025 | Termination of all internal R&D | Completed | Cost rationalisation | AR FY2025 |
| Oct 2025 – Jun 2026 | LOI for 80% of a French CRO (clinical development and regulatory affairs) | Terminated 1 Jun 2026 after due diligence | — | PRs 13 Oct 2025, 1 Jun 2026 |
| 16 Feb 2026 | Axiodis sales and marketing acceleration | Ongoing | Broaden beyond its regional base | PR 16 Feb 2026; H1 2026 |
| 10 Mar 2026 | Fourth amendment to the Atlas funding programme | In force to 2 Mar 2027 | Monthly tranches of 12 convertible bonds | AR FY2025 |
| 19 Mar 2026 | LOI for 75% of an international CRO (Europe, North Africa, Middle East) | Pending / unconfirmed | Target 2025 EBITDA ≈ 20% | PR 19 Mar 2026 |
| 2 Jun 2026 | GLP-1 / peptide / biosimilar clinical-research offering | Launched | Market >$150B by 2029 (company-cited forecasts) | PR 2 Jun 2026 |
| 21 Jul 2026 | Axiodis–KYomed INNOV & CEISO biometrics partnership | Signed | ≈ €110k annual revenue, up to €170k | PR 21 Jul 2026 |
| 30 Sep 2026 | Eclevar MedTech CRO business acquisition (68% NewCo) | Exclusive negotiations | Close by 31 Dec 2026; Eclevar targets ≈ €3M FY2027 revenue | PR 30 Sep 2026 |
Medium-term targets and guidance
Group: no formal revenue, EBITDA or margin guidance.
Subsidiary/target ambitions (not group guidance): - Axiodis: >€2M revenue and 20% EBITDA by 2027.
- Eclevar: ≈ €3M revenue in FY2027.
Funding: management states it must complete further acquisitions before 2 March 2027 to secure the company's survival (AR FY2025 §3.5.1.1).
ESG / sustainability commitments: none quantified.
Products & Services
Current portfolio (CRO platform)
| Offering | Description / capabilities | Target customer | Launch / version | Pricing model | Source |
|---|---|---|---|---|---|
| Clinical Data Management (Axiodis) | Full data cycle: protocol and methodology support, database design, data capture, cleaning, validation, query management, audit-ready documentation | Pharma, biotech, medtech and academic sponsors | Axiodis founded 2022 (first FY 1 Aug 2022 – 31 May 2023) | Per-study service fees (not disclosed in detail) | AR FY2025; H1 2026 |
| Biostatistics | Statistical modelling and analysis plans, analysis execution, regulatory reporting for EMA/FDA submissions | Same | 2022– | Per-study | PR 16 May 2025 |
| Statistical programming / CDISC | Advanced command of CDISC standards (SDTM-aligned data structures) | Same | 2022– | Per-study | PR 16 May 2025; H1 2026 |
| Project management | Coordination of biometrics deliverables, with a network of partners | Same | 2022– | Per-study | H1 2026 |
| Exagis CDMS (proprietary) | Live clinical data management system built by clinical research professionals and already used in operational studies. Modular: eCRF data capture, query workflows, ePRO, eConsent, SDTM-aligned data structure, HDS-compliant secure hosting | Sponsors using Axiodis; positioned as the group's common technology backbone | In operational use. Roadmap: randomisation, clinical supply workflows, advanced analytics, selective AI-assisted tools | Embedded in service fees; standalone licensing n/d | H1 2026 Interim Report |
| Biometrics subcontracting for CROs | Specialist biometrics delivered to full-service CROs that lack in-house capacity (first reference client: KYomed INNOV & CEISO) | Clinical CROs (medtech and digital-health focus) | Jul 2026 | Expected about €110k annual revenue, potentially up to €170k (FinanzWire summary of PR) | PR 21 Jul 2026 |
| GLP-1 / peptide / biosimilar clinical-research offering | Biometrics, CDM, biostatistics and regulatory-grade data flows tailored to peptide-based programmes | Developers of GLP-1, peptide and biosimilar drugs | Launched 2 Jun 2026 | — | PR 2 Jun 2026 |
Prospective portfolio (pending transactions; unconfirmed)
| Prospective offering | Description | Status | Source |
|---|---|---|---|
| Clinical operations / monitoring (international CRO) | Multi-country operational CRO in Europe, North Africa and the Middle East; 2025 EBITDA margin expected around 20% | LOI of 19 Mar 2026; exclusivity to 30 Jun 2026 (extendable). Status after June 2026 not confirmed in retrieved disclosures | PR 19 Mar 2026 |
| MedTech CRO services (Eclevar) | Pre-market clinical investigations, post-market clinical follow-up, regulatory advisory, global study design, EU market access; footprint in Europe, Japan and China | Exclusive negotiations; target close by 31 Dec 2026 | PR 30 Sep 2026 |
Legacy / discontinued portfolio (historical record)
| Asset | Description | Status |
|---|---|---|
| JETREA (ocriplasmin) | Recombinant plasmin derivative for vitreomacular adhesion/traction (pharmacological vitreolysis); approved in 54 countries | Licensed to Inceptua (2020); commercialisation ended 31 Dec 2023 |
| THR-149 | Bicyclic peptide plasma kallikrein inhibitor (licensed from Bicycle Therapeutics) for DME patients who respond suboptimally to anti-VEGF | Failed KALAHARI Part B (Nov 2023); development halted |
| THR-687 | Pan-RGD integrin antagonist (Galapagos-derived) for DME / wet AMD | Not advanced to Phase 2 Part B (2022); intangible disposed 31 Dec 2024 |
| THR-317 | Anti-PlGF antibody, studied in combination with ranibizumab for DME | Discontinued (pre-2021) |
| TB-403 / immuno-oncology (Oncurious) | Anti-PlGF oncology programme; CCR8 and other I-O targets | Impaired 2021; CCR8 assigned to VIB in 2022 with a revenue-sharing right for Oxurion |
| GA CRISPR target-discovery platform | Genome-wide CRISPR screening in a "patient in a dish" GA model | Terminated 7 Aug 2025 |
Financial Narrative
All figures are IFRS consolidated and in EUR thousands unless the row label says otherwise. Sources: AR FY2021 (FY2021), AR FY2023 (FY2022–FY2023), AR FY2025 (FY2024–FY2025).
Income statement
Notes:
-
Selling expenses for FY2024–FY2025 were none in the H1 2025 and H1 2026 interim P&Ls; the full-year FY2024 figure is inferred from the absence of a selling line in AR FY2025 commentary.
-
EPS for FY2021–FY2023 is on a pre-reverse-split basis. FY2024–FY2025 is post-split (1:10,000), so EPS is not comparable across the break.
EBITDA: n/d. An aggregator (Google Finance) shows FY2023 EBITDA of −€2.46M, which conflicts with the reported operating loss of −€12.1M and is not relied on.
Margins and growth (analyst calculations)
-
Revenue CAGR FY2021–FY2025 is −16.2% per year (analyst calculation).
-
Margins are mathematically derived but n/m economically, because of the tiny revenue base and the business-model change.
-
FY2025 gross profit (€0.6M rounded) slightly exceeds rounded revenue (€0.555M), which reflects rounding in the source. The H1 2026 gross margin is 98.8% (584/591).
Commentary. The P&L shows three regimes.
FY2021–FY2023 (clinical-stage burn): Operating losses of €12–28M a year were driven by the KALAHARI and INTEGRAL Phase 2 programmes. R&D fell from €20.7M to €10.0M as programmes were cut.
FY2022–FY2023 finance costs: Finance expense spiked (€9.4M and €7.3M), driven by fair-value and other charges on the Negma, Kreos/Pontifax and Atlas convertible instruments.
FY2024 (restructuring): Oxurion posted a rare positive operating result (+€0.4M) and net profit (+€0.1M). This was not operational. It came from €4.1M of other operating income, consistent with creditor write-downs and settlement gains in the judicial reorganisation, plus vendor settlements of about €1.0M (statutory).
FY2025 (pivot): Axiodis was consolidated for five months (€555k revenue). The holding-company cost base, including R&D up to the August termination, produced a €3.3M operating loss.
Interim trend (H1 2026 vs H1 2025)
Source: H1 2026 Interim Report.
Analyst note: H1 2026 still carries €0.74M of "R&D expenses," although all R&D was terminated in August 2025. This most plausibly reflects Exagis software development and Axiodis technical staff costs classified as R&D. The classification is not explained in the interim report.
Balance sheet
Debt split: convertible loans are classified as current in FY2025 (€11.3M) and H1 2026 (€11.4M). Lease liabilities are €48k non-current and €81k current at 30 Jun 2026. Total debt in H1 2026 is about €11.5M, all effectively short-term.
H1 2026 balance sheet: total assets €3,435k; cash €31k; equity −€13,294k; current liabilities €16,393k, including trade payables of €2,848k.
Commentary. The balance sheet is deeply insolvent on a book basis. Equity has been negative since FY2021, and net assets have been below the €61,500 statutory minimum since 27 March 2025, which exposes the company to dissolution claims under BCCA art. 7:229. The convertible-loan stack (about €11.3M, mostly Atlas and the assigned former Kreos/Pontifax facility) is roughly 3× total assets. The largest remaining non-cash asset is the Belgian R&D tax credit receivable (€1.17M non-current plus €0.99M current at YE2025). Management explicitly relies on this receivable to bridge its funding gap.
Cash flow
- A secondary aggregator (Stoxray) shows −€27.2M (FY2021), −€20.0M (FY2022) and −€9.8M (FY2023). Google Finance shows −€1.43M for FY2023, a material conflict.
Free cash flow: n/m. It was approximately equal to operating cash flow, since capex was negligible (≤€0.06M a year).
Interim operating cash flow: −€1,128k (H1 2025) and −€573k (H1 2026).
Ratios (analyst calculations)
The following ratios are n/m in all years:
ROE: equity is negative in every year.
ROIC: invested capital is negative or undefined.
Debt/equity: equity is negative.
Net debt/EBITDA: EBITDA is negative or undisclosed.
Interest coverage: operating income is negative except in FY2024.
Cash conversion cycle: n/d.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Activity (EUR K) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
JETREA-related income (vials and royalties) | 1,128 | 595 | 263 | 3 | 0 |
CRO services (Axiodis, consolidated from 1 Aug 2025) | 0 | 0 | 0 | 0 | 555 |
Total consolidated income | 1,128 | 595 | 263 | 3 | 555 |
Revenue by Segment
| Legacy product split, statutory (EUR Mn) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Product sales (JETREA vials) | 1.1 | 0.4 | 0.2 |
Royalties | 0.2 | 0.2 | 0.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (EUR K) | 263 | 3 | 555 |
YoY revenue growth (%) | -55.8 | -98.9 | 18,400 |
CRO services share of revenue (%) | 0 | 0 | 100 |
Group Entities
| Entity | Jurisdiction | Ownership | Function / status |
|---|---|---|---|
Oxurion NV | Leuven, Belgium | Listed parent | Holding company, listing, M&A |
Axiodis CRO SAS | Toulouse, France | 72% (28% founders/employees, with a put option exercisable from 2029) | Sole operating subsidiary: biometrics, CDM, Exagis eCRF/CDMS |
Oxurion France SAS | Toulouse, France | 100% | Non-operational acquisition holding company (created 24 Dec 2024); lends to Axiodis via a shareholder loan |
ThromboGenics, Inc. | New York, USA | 100% | Legacy US subsidiary; dormant |
Oncurious NV | Leuven, Belgium | 100% | Legacy oncology subsidiary; assets impaired/assigned; dormant |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue / income (EUR K) | 1,128 | 595 | 263 | 3 | 555 |
Gross profit (EUR Mn) | 0.5 | 0.1 | 0.1 | -0.04 | 0.6 |
R&D expenses (EUR Mn) | 20.7 | 16.0 | 10.0 | 1.4 | 1.8 |
Selling expenses (EUR Mn) | 1.3 | 0.9 | 0.1 | 0 | 0 |
G&A expenses (EUR Mn) | 7.2 | 6.0 | 3.7 | 2.3 | 2.3 |
Other operating income (EUR Mn) | 1.2 | 0.8 | 1.7 | 4.1 | 0.4 |
Operating result (EUR K) | -28,495 | -22,946 | -12,110 | 382 | -3,291 |
Finance income (EUR K) | 171 | 639 | 414 | 323 | 360 |
Finance expense (EUR K) | -1,268 | -9,379 | -7,270 | -583 | -767 |
Pre-tax result (EUR K) | -29,592 | -31,686 | -18,966 | 122 | -3,698 |
Net result (EUR K) | -29,595 | -31,693 | -18,969 | 119 | -3,708 |
Basic EPS (EUR) | -0.77 | -0.37 | -0.01 | 0.09 | -0.13 |
Diluted EPS (EUR) | -0.77 | -0.37 | -0.01 | 0.00 | -0.13 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 44.3 | 16.8 | 38.0 | -1,333 | 108.1 |
Operating margin (%) | -2,526 | -3,856 | -4,605 | 12,733 | -593 |
Net margin (%) | -2,624 | -5,327 | -7,213 | 3,967 | -668 |
Revenue YoY growth (%) | -45.7 | -47.3 | -55.8 | -98.9 | 18,400 |
Cash Flow
| Metric (EUR K) | H1 2025 | H1 2026 |
|---|---|---|
Sales | 0 | 591 |
Gross profit | 0 | 584 |
R&D expenses | -705 | -740 |
G&A expenses | -1,178 | -868 |
Other operating income | 92 | 269 |
Operating result | -1,794 | -755 |
Finance income | 602 | 0 |
Finance expense | 5 | -142 |
Net result | -1,187 | -904 |
Net result attributable to equity holders | -1,187 | -918 |
Non-controlling interest | 0 | 14 |
Operating cash flow | -1,128 | -573 |
Financing cash flow | 570 | 175 |
Balance Sheet
| Metric (EUR K) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 18,876 | 11,993 | 6,550 | 5,695 | 3,825 |
Cash and cash equivalents | 9,740 | 3,496 | 1,624 | 455 | 430 |
Current investments | 247 | 95 | 50 | 0 | 0 |
Goodwill | 0 | 0 | 0 | 0 | 182 |
Intangible assets | 1,000 | 0 | 0 | 0 | 483 |
Non-current R&D tax credit | 4,000 | 3,785 | 3,525 | 2,030 | 1,169 |
Trade and other receivables | 2,517 | 3,321 | 878 | 2,385 | 384 |
Total equity | -1,108 | -4,583 | -13,186 | -11,058 | -12,689 |
Non-current liabilities | 9,071 | 4,227 | 129 | 130 | 336 |
Current liabilities | 10,913 | 12,349 | 19,607 | 16,623 | 16,178 |
Convertible loans (EUR Mn) | 11.8 | 7.0 | 12.0 | 11.2 | 11.3 |
Working capital (current assets − current liabilities) | 2,496 | -5,243 | -16,867 | -13,038 | -14,371 |
Net debt (convertible loans − cash & investments; EUR Mn) | 1.8 | 3.4 | 10.3 | 10.7 | 10.9 |
Cash Flow (Annual)
| Metric (EUR K) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capex (statutory investments) | 20 | 60 | 0 | 0 | 0 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Year-end cash incl. investments (EUR Mn) | 10.0 | 3.6 | 1.7 | 0.5 | 0.4 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROA (net result / total assets, %) | -156.8 | -264.3 | -289.6 | 2.1 | -96.9 |
Current ratio (x) | 1.23 | 0.58 | 0.14 | 0.22 | 0.11 |
Asset turnover (revenue / total assets, x) | 0.06 | 0.05 | 0.04 | 0.00 | 0.15 |
Disclosure Point Details
| Disclosure point | Figure | Source |
|---|---|---|
Atlas programme total commitment | €20.0M (conditional) | AR FY2023 |
Drawn by 31 Dec 2023 | €11.5M | AR FY2023 |
Drawn by 31 Dec 2025 | €16.35M (€3.65M remaining) | AR FY2025 |
Drawn by 30 Jun 2026 | €16.65M (€3.35M remaining) | H1 2026 |
Actual Atlas receipts in 2025 vs plan | €1.75M received vs €3.6M planned | AR FY2025 |
Monthly cash need | ≈ €0.32–0.35M | AR FY2025; H1 2026 |
Shortfall to Oct 2027 (absent funding) | ≈ €3.9M | H1 2026 |
Cash on 14 Apr 2026 | ≈ €11k | AR FY2025 |
Funding horizon | Atlas funding ends 2 Mar 2027; no financing in place after that date | AR FY2025 |
Revenue by Region
| Region (EUR K) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Belgium | 1,128 | 595 | 263 | 3 | 0 |
France | 0 | 0 | 0 | 0 | 555 |
Region growth (%)
| Region growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Belgium | -55.8 | -98.9 | -100 |
France | 0 | 0 | 100 |
Capital Markets
| Indicator | Value | Source |
|---|---|---|
Last price (16 Oct 2026) | €0.0008 | MarketScreener |
5-day change | -33.33% | MarketScreener |
Year-to-date change (2026) | -88.89% | MarketScreener |
≈ 1-year change | ≈ -94.8% | MarketScreener (column interpretation) |
3-year / 5-year change | ≈ -99.99% (also affected by the 1:10,000 reverse split and conversion dilution) | MarketScreener |
2025 high | €0.1001 (17 Apr 2025) | AR FY2025 |
2026 reference points | €0.0042 (14 Apr 2026); €0.0026 (2 Jun 2026); €0.0014 (30 Sep 2026) | AR FY2025; ABC Bourse |
Post-split reference | ≈ €0.30, market cap ≈ €0.58M (29 Oct 2024) | Craft.co (secondary) |
Share count (millions; post-split basis unless noted) | Sep 2024 | Dec 2025 |
Shares outstanding | 1.34 | 62.60 |
Valuation Multiples
| Multiple | Oxurion | Basis |
|---|---|---|
Market cap (EUR Mn) | 0.19 | 232.0M × €0.0008 |
Enterprise value (EUR Mn) | ≈ 11.5 | Market cap + €11.38M convertible loans + €0.13M leases − €0.03M cash (30 Jun 2026) |
EV / LTM sales (x) | ≈ 10.0 | LTM sales ≈ €1.15M (FY2025 €555k + H1 2026 €591k − H1 2025 €0) |
P/E | n/m | Loss-making |
EV / EBITDA | n/m | EBITDA negative / n/d |
P/B | n/m | Negative book equity |
Capital Instruments
| Instrument | Amount | Maturity / terms |
|---|---|---|
Atlas convertible bonds (outstanding, unconverted) | Included in €11.38M convertible loans (30 Jun 2026) | Mandatory convertibles. Default interest of 20% p.a. on an Event of Default |
Former Kreos/Pontifax loan (assigned to Atlas) | Included above | Repayment extended to 31 May 2027 |
Lease liabilities | €129k | €81k current; €48k non-current |
Security | Second-ranking pledge on all movable business assets (up to €8.5M under the 2023 terms) | — |
Analyst Conclusions
Management guidance
There is no formal group guidance. Management's qualitative outlook (AR FY2025 CEO letter; H1 2026 report) for 2026 calls for:
-
full integration of the technology capabilities;
-
completion of the "next strategic move";
-
acceleration of international expansion.
Subsidiary and target ambitions are Axiodis >€2M revenue and 20% EBITDA by 2027, and Eclevar ≈ €3M revenue in FY2027.
Consensus
There is no sell-side consensus.
Bull case
-
Accretive, near-free acquisitions. If both pending deals close, pro forma revenue could plausibly approach €5M or more. The inputs are Axiodis ≈ €1.0M, Eclevar ≈ €2.5M normalised, and an international CRO valued at ≈ €3.7M on a 100% basis at roughly 20% EBITDA. Oxurion would pay almost no upfront cash, deferring payment through EBITDA- or revenue-linked puts.
-
Operating leverage. The H1 2026 gross margin of 98.8% and an operating loss that narrowed from €1.79M to €0.76M year on year show the cost base is now small. Modest revenue scale could reach operating break-even.
-
Structural tailwinds. Biometrics outsourcing (≈ 7–8% CAGR), EU MDR-driven medtech evidence demand and GLP-1/biosimilar trial volumes all favour small, specialised data-centric CROs that full-service CROs subcontract to (the KYomed model).
Bear case
-
Insolvency arithmetic. Cash is €31k, equity is −€13.3M and convertible debt is €11.4M. Atlas funding expires on 2 March 2027 and depends on market-cap and liquidity thresholds the stock barely meets. The company itself states its going concern is "permanently threatened."
-
Value capture goes to creditors, not shareholders. Shares outstanding rose about 2.6× in seven months of 2026. Management explicitly calls recovery prospects for existing shareholders "remote." Any enterprise value created is likely to accrue to Atlas through conversions.
-
Execution record. Two acquisition processes have been terminated and one remains unconfirmed. The crypto-treasury plan was announced and then suspended. AGMs have been postponed twice. Management has never run a CRO. Axiodis's top client is about 50% of revenue.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Signing and closing of Eclevar definitive agreements | By 31 Dec 2026 (target) |
| Status update on the international CRO LOI (exclusivity lapsed 30 Jun 2026 unless extended) | Undated |
| Monthly Atlas tranche drawdowns and conversion pace (denominator notices) | Monthly |
| Any dissolution petition under BCCA art. 7:229, or an Atlas Event-of-Default notice | Ongoing |
| FY2026 annual report and audit opinion | ≈ April 2027 |
| New financing to replace Atlas after 2 March 2027 | Before March 2027 |
| Axiodis client wins and diversification (KYomed-type partnerships; GLP-1 mandates) | Ongoing |
| Former Kreos/Pontifax loan repayment deadline | 31 May 2027 |
Analyst verdict
Oxurion NV is no longer the company its identifiers suggest. The ophthalmology biotech that brought JETREA to 54 countries effectively ended with the THR-149 failure in November 2023. The listed entity today is a distressed micro-cap holding company with a market value of roughly €0.2 million. Its only operating asset is a 72% stake in Axiodis CRO, a well-run but tiny Toulouse biometrics business: about €1.0 million in revenue, profitable, and with a proprietary CDMS.
The strategic logic is coherent. Buying small European CROs at low multiples with deferred, performance-based consideration, and linking them through a shared eClinical platform, is a recognised roll-up model in a fragmented, growing market. The H1 2026 numbers show the first consolidated CRO revenue (€591k) and a much smaller operating loss.
But the capital structure dominates the investment case. Negative equity of €13.3 million, €11.4 million of convertible debt held by the same investor that converts and sells shares continuously, cash of €31k, and a funding programme that ends on 2 March 2027 together mean that equity holders sit behind a creditor with presumed de facto control. Net assets have been below the statutory minimum since March 2025. The auditor has flagged material going-concern uncertainty for three consecutive years. M&A execution has been inconsistent, and management has never operated a CRO.
For institutional purposes we classify Oxurion as uninvestable equity / special situation. The business has option value tied to closing Eclevar and the international CRO and to securing non-Atlas financing before March 2027. However, the dilution mechanics make it unlikely that existing shareholders capture that value, as the company itself acknowledges. Relevant counterparties (sponsors, target vendors and creditors) should treat Oxurion as a high-counterparty-risk entity and focus diligence on Axiodis on a standalone basis. The key signals to monitor are the next denominator notices and any Atlas default notice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age | Compensation |
|---|---|---|---|---|---|
Pascal Ghoson (via MARS SARL) | CEO & CFO; Executive Director | Since 28 Dec 2023 | Previously Administrative & Financial Director of SA Energisme from May 2023 (Simply Wall St, secondary). Education n/d | 37 (Zonebourse, secondary) | FY2024 total ≈ €280k, of which ≈ €270k salary (Simply Wall St, secondary). FY2025: fixed fee plus a one-off discretionary bonus approved by the board (amount n/d in retrieved extract; AR FY2025 §4.2) |
Andy De Deene | Corporate officer / Chief Development Officer (legacy) | Since 2008 per Zonebourse | Legacy development function | — | — |
Axiodis CRO management (CEO name n/d) | Subsidiary management | Retained post-acquisition | Founders retain 28% of Axiodis | — | — |
Board of Directors
| Name | Role | Independence | Since | Background |
|---|---|---|---|---|
Charles Paris de Bollardière | Chair, Non-Executive Director | Non-executive; Atlas proposed the December 2023 co-optees | 28 Dec 2023 | n/d in retrieved sources |
Pascal Ghoson | CEO & CFO, Executive Director | Executive | 28 Dec 2023 | See above |
James Hartmann | Independent Non-Executive Director | Independent (per company) | 28 Dec 2023 | Age 60 (Zonebourse) |
Nelly Souleymane | Independent Non-Executive Director | Independent | Co-opted from 13 Jan 2025 (announced 14 Feb 2025) | About 19 years in corporate communications, reputation management and public affairs, a significant part at Bayer |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
May 2021 | Tom Graney appointed CEO (joined Oct 2020) | Graney-era clinical focus |
28 Dec 2023 | Board and management replaced. Pascal Ghoson CEO; Charles Paris de Bollardière Chair; James Hartmann director | Atlas rescue after KALAHARI failure |
| 2023 | Settlement agreements with former board members (non-recurring income ≈ €0.5M, statutory) | AR FY2023 |
13 Jan 2025 | Anat Loewenstein and Nathalie Laarakker depart; Nelly Souleymane co-opted | PR 14 Feb 2025 |
Major Shareholders
| Holder | Shares | % of outstanding | As of | Source |
|---|---|---|---|---|
Atlas Special Opportunities II LLC | 55,555,555 | ≈ 23.9 (crossed above 20%) | 9 Oct 2026 | Transparency notice, 14 Oct 2026 |
Atlas Special Opportunities II LLC (earlier reference) | 18,592,918 | 20.96 | 17 Mar 2026 | AR FY2025 |
Atlas Special Opportunities II LLC (earlier reference) | 8,573,332 | 9.67 | 29 Apr 2026 | Whiteford Research (secondary) |
Market Wizards B.V. | 5,304,604 | < 3 (crossed below) | 8 Oct 2026 | Transparency notice, 12 Oct 2026 |
UBS Group AG | — | Transparency notification filed | Sep 2025 | Euronext press-release list |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Scale indicator | Relative positioning vs Oxurion/Axiodis |
|---|---|---|---|---|
Full-service global CRO | IQVIA (US) | Tier-1 CRO | ≈ $15B revenue (CCRPS 2025 directory, secondary); largest CRO services share in 2023 (MarketsandMarkets) | Several thousand times larger; also a potential client channel |
Full-service global CRO | ICON plc (Ireland) | Tier-1 CRO | ≈ $6.5B revenue (CCRPS, secondary) | Dominant; owns PRA Health Sciences |
Full-service global CRO | Thermo Fisher (PPD) (US) | Tier-1 CRO | n/d here | Dominant |
Full-service global CRO | Labcorp / Fortrea (US) | Tier-1 CRO | n/d (secondary figures unreliable) | Dominant |
Full-service global CRO | Medpace, Parexel, Syneos Health | Tier-1/2 CROs | — | Dominant in biotech outsourcing |
European mid-size CRO | PSI CRO (Switzerland) | Mid-size | ≈ $600M (CCRPS, secondary) | Strong European operational CRO |
European mid-size CRO | KCR (Poland) | Mid-size | ≈ $200M (CCRPS, secondary) | Competes for the European biotech clients Oxurion seeks |
European mid-size CRO | Ergomed (UK) | Mid-size | ≈ $250M (CCRPS, secondary) | Overlap in rare disease / oncology |
European specialist / early phase | Biotrial (France) | Specialist | ≈ $100M (CCRPS, secondary) | French competitor |
Biometrics specialist | Cmed (UK) | Specialist | ≈ $50M (CCRPS, secondary) | Direct biometrics competitor; much larger |
eClinical / CDMS software | Medidata (Dassault Systèmes), Veeva, Oracle, OpenClinica, Ennov, eClinical Solutions | Software | Market leaders (GMI Insights) | Exagis competes as a niche, service-embedded CDMS |
MedTech CRO (Eclevar adjacency) | Specialist MedTech CROs (names n/d in sources) | Specialist | — | Eclevar ≈ €2.5M normalised revenue |
Peer Comparison FY2025
| Company | Revenue (USD Mn, approx.) | Operating margin | R&D intensity |
|---|---|---|---|
Oxurion (FY2025, EUR 0.555M ≈ USD 0.6M) | 0.6 | -593% | 324% of revenue |
IQVIA | 15,000 | — | — |
ICON | 6,500 | — | — |
PSI CRO | 600 | — | — |



